TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Brief Summary: The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EPO | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EPO; Assigned to Arm(s): 1
B: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.


Options:
A: Arm Label: Aclidinium bromide 100 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 100 μg bid | Arm Label: Aclidininum bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidininum bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Formoterol 12 μg bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol 12 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 100 μg bid; Assigned to Arm(s): Aclidinium bromide 100 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidininum bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidininum bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol 12 μg bid; Assigned to Arm(s): Formoterol 12 μg bid
B: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Aclidinium; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.


Options:
A: Arm Label: Fluticasone Furoate Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: FF Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: Fluticasone Furoate/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Pwdr, Fluticasone Furoate Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Pwdr, Fluticasone Furoate/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
C: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol, Drug: Fluticasone Propionate/Salmeterol Combination Product | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219)
Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Oral cromolyn; Type: EXPERIMENTAL; Interventions: Drug: oral cromolyn sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral cromolyn sodium; Assigned to Arm(s): Oral cromolyn | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: APT-1011 1.5 mg HS; Type: EXPERIMENTAL; Interventions: Drug: APT-1011, Drug: Placebo | Arm Label: APT-1011 1.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: APT-1011 | Arm Label: APT-1011 3 mg HS; Type: EXPERIMENTAL; Interventions: Drug: APT-1011, Drug: Placebo | Arm Label: APT-1011 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: APT-1011 | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: APT-1011; Assigned to Arm(s): APT-1011 1.5 mg BID, APT-1011 1.5 mg HS, APT-1011 3 mg BID, APT-1011 3 mg HS | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): APT-1011 1.5 mg HS, APT-1011 3 mg HS, Placebo BID
D: Arm Label: Mepolizumab 0.55 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: mepolizumab | Arm Label: Mepolizumab 2.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: mepolizumab | Arm Label: Mepolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: mepolizumab | Intervention Type: DRUG; Name: mepolizumab; Assigned to Arm(s): Mepolizumab 0.55 mg/kg, Mepolizumab 10 mg/kg, Mepolizumab 2.5 mg/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Brief Summary: The study will evaluate the safety and tolerability, optimal biologic dose, and pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet count and are receiving ADRIAMYCIN and ifosfamide (AI) chemotherapy.


Options:
A: Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): Group A, Group B
B: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): Arm 1, Arm 2, Arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: Eltrombopag; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eltrombopag olamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Eltrombopag olamine; Assigned to Arm(s): Eltrombopag | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blinded Multi-centre Trial Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest at the Emergency Department. (Preadmission Intravenous Vasopressin, Adrenaline Outcome Trial: PIVOT vII)
Brief Summary: The effectiveness of medications in cardiac arrest has been greatly debated and questioned. Historically intravenous adrenaline has been the drug of choice since 1906. There have been few formal evaluations to determine the value of adrenaline for cardiac arrest, and clinical trials have not been able to show any benefit with intravenous adrenaline (compared to placebo or no treatment) in the field.

Thus the purpose of this study is to compare vasopressin and adrenaline in the treatment of cardiac arrest to answer the question whether there is an improvement in survival between vasopressin and adrenaline.


Options:
A: Arm Label: Adrenaline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adrenaline | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Adrenaline; Assigned to Arm(s): Adrenaline | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin
B: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Epinephrine, Placebo | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Drug: Vasopressin, Epinephrine, and Steroids | Intervention Type: DRUG; Name: Vasopressin, Epinephrine, and Steroids; Assigned to Arm(s): Study Group | Intervention Type: DRUG; Name: Placebo, Epinephrine, Placebo; Assigned to Arm(s): Control Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: OTHER; Interventions: Other: Manual | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: epinephrine (1 mg/1 mL); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: arginine-vasopressin (40 UI/2 mL); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Satavaptan Cirrhotic Ascites Treatment Study: a Double-blind, Randomised, Parallel-group Comparison of Treatment With Satavaptan at 5 to 10 mg Daily Versus Placebo on Top of Conventional Treatment in Patients With Ascites Due to Cirrhosis of the Liver
Brief Summary: Primary:To evaluate the efficacy of satavaptan on top of conventional treatment in the treatment of clinically evident ascites in participants with cirrhosis of the liver.

Secondary:To evaluate the tolerability and safety of satavaptan over a 52-week treatment period in participants with cirrhosis of the liver and ascites.

The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).


Options:
A: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: satavaptan (SR121463B); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Prevention of Obesity Through Infancy Interventions
Brief Summary: Childhood obesity has reached epidemic proportions and its prevalence continues to rise, even among very young children. Because the current evidence base regarding potentially effective early intervention components to prevent obesity is so incomplete, it is logical to initiate obesity prevention intervention research during infancy, focusing on the two major components of the infant lifestyle, sleeping and feeding.


Options:
A: Arm Label: A&T Intervention Communes; Type: EXPERIMENTAL; Interventions: Behavioral: A&T infant and young child feeding intervention | Arm Label: Control Communes; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: A&T infant and young child feeding intervention; Assigned to Arm(s): A&T Intervention Communes
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Repeated Food Exposure | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing, Behavioral: Repeated Food Exposure | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Infant Sleeping and Soothing; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Repeated Food Exposure; Assigned to Arm(s): 2, 3
C: Arm Label: Breast feeding optimization; Type: EXPERIMENTAL; Interventions: Behavioral: Breast feeding optimization, Behavioral: Usual care | Arm Label: Usual/routine care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Breast feeding optimization; Assigned to Arm(s): Breast feeding optimization | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Breast feeding optimization, Usual/routine care
D: Arm Label: eHealth Intervention; Type: EXPERIMENTAL; Interventions: Other: eHealth Breastfeeding Co-parenting Resource | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: eHealth Breastfeeding Co-parenting Resource; Assigned to Arm(s): eHealth Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Prevention of Obesity Through Infancy Interventions
Brief Summary: Childhood obesity has reached epidemic proportions and its prevalence continues to rise, even among very young children. Because the current evidence base regarding potentially effective early intervention components to prevent obesity is so incomplete, it is logical to initiate obesity prevention intervention research during infancy, focusing on the two major components of the infant lifestyle, sleeping and feeding.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Repeated Food Exposure | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing, Behavioral: Repeated Food Exposure | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Infant Sleeping and Soothing; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Repeated Food Exposure; Assigned to Arm(s): 2, 3
B: Arm Label: Healthy Start to Feeding Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Start to Feeding | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy Start to Feeding; Assigned to Arm(s): Healthy Start to Feeding Intervention
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
D: Arm Label: visit with grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: visit without grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: no visit with grandmother; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: no visit without grandmother; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: counseling sessions; Assigned to Arm(s): visit with grandmother, visit without grandmother

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Prevention of Obesity Through Infancy Interventions
Brief Summary: Childhood obesity has reached epidemic proportions and its prevalence continues to rise, even among very young children. Because the current evidence base regarding potentially effective early intervention components to prevent obesity is so incomplete, it is logical to initiate obesity prevention intervention research during infancy, focusing on the two major components of the infant lifestyle, sleeping and feeding.


Options:
A: Arm Label: Home-Based Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Home-Based Health Coaching | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mailed materials | Intervention Type: BEHAVIORAL; Name: Home-Based Health Coaching; Assigned to Arm(s): Home-Based Health Coaching | Intervention Type: BEHAVIORAL; Name: Mailed materials; Assigned to Arm(s): Control Arm
B: Arm Label: Physical Activity Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Intervention; Assigned to Arm(s): Physical Activity Intervention
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Repeated Food Exposure | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing, Behavioral: Repeated Food Exposure | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Infant Sleeping and Soothing; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Repeated Food Exposure; Assigned to Arm(s): 2, 3

Answer: D